For July 2026, CStone Pharmaceuticals reported a net reduction of 4.47 million ordinary shares, bringing total issued shares (excluding treasury shares) to 1.60 billion. The decline reflects 4.60 million shares cancelled after two repurchase programmes, partially offset by 0.12 million new shares issued from employee option exercises.

CStone’s authorised share capital was unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.20 million.

Share-based incentives remained active: • Pre-IPO Incentivization Plan: 96,344 options were exercised, cutting the outstanding balance to 1.07 million. • Post-IPO Employee Share Option Plan: 28,125 options were exercised, leaving 104.80 million options outstanding and 37.07 million further shares available for future grants. Total proceeds from option exercises reached HKD 0.18 million.

Repurchases were the primary driver of the net share count contraction: • 3.34 million shares bought back under a June 2025 mandate and cancelled on 27 July 2026. • 1.26 million shares repurchased under a June 2026 mandate and cancelled on the same date. No treasury shares were held at month-end.

Following these movements, CStone affirmed that its public float exceeded the Main Board’s 25% minimum requirement.